To The Moon

The U.S. Navy has restarted assisting vessel crossings through the Strait of Hormuz, according to U.S. military officials.The officials told The Wall Street Journal that a Greek supertanker laden...

Singapore Q1 GDP Growth Rate YoY Final +6.0% (Est. +5.1%, Prior +4.6%)

President Donald Trump will host the swearing-in of new Federal Reserve Chair Kevin Warsh on Friday morning, the first time a central bank chief has taken the oath of office in the White House in...

Iran And Oman Discussing a Permanent Hormuz Toll: Iranian Envoy

WTI crude oil futures dropped nearly 4% to $100.04 a barrel; Brent oil futures fell 4.16% to $106.65 a barrel.The Pakistani Army Leader May Visit Iran Tomorrow to Announce the Final Version of The...

Ericsson has formed a partnership with Net Feasa to provide real-time 4G and 5G connectivity and cargo monitoring for the maritime shipping industry, Ericsson said Tuesday.The system is designed to give shipping companies and port operators continuous visibility into cargo conditions and vessel operations while at sea, using AI-ready data and connected sensors.The platform can support thousands of connected assets per vessel and is already being deployed globally, the company said.

Air China's stock price plummeted 5.21% during intraday trading on Friday, reflecting significant selling pressure in the airline sector.The sharp decline follows reports that domestic airlines are...

US April CPI YoY +3.8% (Est. +3.7%, Prior +3.3%)

Beijing officially announced the date of Donald Trump’s state visit this week, publicly green-lighti

Bristol Myers Squibb said Friday that the European Commission approved Sotyktu for adults with active psoriatic arthritis who had an inadequate response or intolerance to prior disease-modifying antirheumatic drug therapy.Sotyktu is the first and only TYK2 inhibitor approved in the EU for active psoriatic arthritis and can be used alone or with methotrexate, the company said.The approval was supported by Phase 3 POETYK PsA-1 and PsA-2 trial results showing Sotyktu outperformed placebo at Week 16 across joint and skin symptom measures and quality-of-life endpoints, the company added.